title: Shiga toxin associated hemolytic uremic syndrome.
abstract: Shiga toxin associated hemolytic uremic syndrome (Stx HUS), a thrombotic microangiopathy, is the most common cause of pediatric acute kidney injury but has no direct treatment. A better understanding of disease pathogenesis may help identify new therapeutic targets. For this reason, the role of complement is being actively studied while eculizumab, the C5 monoclonal antibody, is being used to treat Stx HUS but with conflicting results. A randomized controlled trial would help properly evaluate its use in Stx HUS while more research is required to fully evaluate the role complement plays in the disease pathogenesis.
authors.affiliation: Department of Molecular and Cell Biology, The Scripps Research Institute, MB 216, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA; Academic Renal Unit, University of Bristol, Dorothy Hodgkin Building, Whitson Street, Bristol BS1 3NY, UK. Electronic address: lskeir@doctors.org.uk.
authors.forename: Lindsay Susan
authors.initials: LS
authors.lastname: Keir
mesh_terms: D058186:Acute Kidney Injury / Q000209:etiology / Q000276:immunology*; D002648:Child; D003170:Complement Pathway, Alternative / Q000276:immunology; D003165:Complement System Proteins / Q000276:immunology / Q000378:metabolism; D006463:Hemolytic-Uremic Syndrome / Q000150:complications / Q000276:immunology* / Q000382:microbiology; D006801:Humans; D018448:Models, Immunological; D022621:Shiga Toxin / Q000276:immunology* / Q000378:metabolism; D054323:Shiga-Toxigenic Escherichia coli / Q000276:immunology* / Q000378:metabolism / Q000502:physiology; D057049:Thrombotic Microangiopathies / Q000150:complications / Q000276:immunology*
chemical_list: D022621:Shiga Toxin; D003165:Complement System Proteins
keywords: Complement; Eculizumab; Shiga toxin; Thrombotic microangiopathy